CCAAT/enhancer binding protein alpha (CEBPA) alterations are more prevalent in hematologic malignancies,27 where CEBPA mutations have been associated with improved outcomes in pediatric and adult acute myeloid leukemia.28 Here, CEBPA is linked to hematologic disorder.